Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesNeuralink’s 2025 story was about early clinical development, not a public launch: the company reported five people with severe paralysis using its technology in June, and in July announced its first clinical study in Great Britain. Those milestones show that research was expanding; they do not establish that the implant is effective, safe for general use, or available to buy.
What Neuralink did in 2025
| Date | Milestone | What it establishes |
|---|---|---|
| January 13, 2025 | Associated Press reported Elon Musk’s claim that a third person had received a Neuralink implant. | A claim attributed to Musk, not an independently verified trial count. AP also described activities earlier participants had publicly demonstrated and quoted experts who said safety, feasibility and comparative advantages remained open questions. |
| May 1, 2025 | Neuralink announced FDA Breakthrough Device Designation for its speech-restoration program. | A regulatory development milestone, not authorization to market the device or evidence that it restores speech. |
| June 2, 2025 | Neuralink announced a $650 million Series E funding round. The company said five people with severe paralysis were using its technology to control digital and physical devices, and described trials across three countries and two continents. | Company-reported funding, participant count and trial reach—not independently audited clinical outcomes. |
| July 31, 2025 | Neuralink announced GB-PRIME, its first clinical study in Great Britain. UCLH identified itself as the lead site. | A new research study, with approvals reported from the MHRA, HRA, HCRW and the London–Camberwell St Giles Research Ethics Committee. These are approvals for the study, not commercial availability. |
The timeline covers the dated milestones described by Neuralink, AP and UCLH; it does not establish the final number of people implanted during all of 2025 or completed efficacy results.
How the N1 implant is intended to work
UCLH describes the N1 as a fully implantable, intracortical brain-computer interface (BCI). More than 1,000 electrodes on fine threads record neural signals. Those signals are sent wirelessly to a computer, where an application is intended to decode them into commands such as moving a cursor, clicking or typing. A surgical robot called R1 places the threads in the brain.
That is the study device’s intended operation, not a guarantee of how well it will work for an individual. The aim is to translate neural activity into device commands; the description alone does not demonstrate reliable control or a clinical benefit.
Recommended Free Tools
#1 Best Overall
Who may be eligible for GB-PRIME, and what participation involves
UCLH describes GB-PRIME as a multi-site feasibility study evaluating safety and functionality. It is for people in Great Britain with tetraplegia or tetraparesis—or a diagnosis that may lead to either condition—whose ability to manually control a computer, smartphone or tablet is significantly impaired or impossible. UCLH says the study may include up to seven participants in Great Britain. This is a study-specific eligibility description, not a guarantee of acceptance.
Time commitment described by UCLH
- The primary study lasts 12 months and includes at least nine in-person visits to a study site.
- Participants are expected to attend structured sessions at least three times a week.
- A three-year long-term follow-up is described, with visits every three months.
UCLH says the implant and R1 robot are investigational medical devices approved for use in this research study. GB-PRIME does not include control of a robotic arm. UCLH identifies robotic-arm control as part of the separate U.S. CONVOY study, so the two studies should not be conflated.
Is Neuralink available to the public?
The 2025 announcements describe clinical research, not a product consumers can purchase or a treatment available by ordinary prescription. GB-PRIME’s approvals permit the study activity described by UCLH; they do not establish approval for commercial sale. The cited materials also do not establish a current U.S. PRIME recruitment status, enrollment figure or posted results. ClinicalTrials.gov explains that study details are submitted by sponsors or investigators, who remain responsible for their accuracy and for the study’s safety and science; a registry listing by itself does not mean the U.S. government has reviewed or approved those matters.
Do the speech and vision programs mean Neuralink can restore those abilities?
No efficacy conclusion follows from the designations alone. Neuralink announced Breakthrough Device Designation for its speech program on May 1, 2025, and for Blindsight on September 17, 2024. A designation is not FDA marketing authorization and is not proof that a device works. The cited announcements establish program milestones, not demonstrated speech or vision restoration.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What remains uncertain about safety and benefit?
The 2025 milestones do not settle whether the N1 is safe and functional over time, how much benefit participants may experience, or how its results compare with other BCI approaches. In AP’s January 2025 coverage, University of Washington neurotechnology co-director Rajesh Rao said Neuralink’s advantages had yet to be shown; he noted its robotic placement of flexible threads and potential to record from more neurons. Christopher & Dana Reeve Foundation chief scientific officer Marco Baptista said, “It’s a little early to know.” These are expert perspectives on an evolving field, not final judgments about outcomes.
UCLH Chief Investigator Harith Akram, a consultant neurosurgeon and UCL associate professor, called the launch of GB-PRIME “a major milestone in the development of brain-computer interface technology, with the potential to transform the lives of people living with severe neurological disorders worldwide.” That is an attributed statement of potential, not an independent finding that the technology has transformed lives.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
